Independent research on the U.S. markets, Baptista Research

Baptista Research

Independent research on the U.S. markets

Baptista Research is an independent financial research house focused on the U.S. markets. We provide equity research as well as credit research reports on the top-listed U.S. companies with most of our focus on technology, consumer goods and services, automobiles, industrials, oil and gas, pharma, and healthcare. Our research has served more than 3000 institutional investors including mutual funds, hedge funds, banks, family offices, and various buy-side firms. We operate a research subscription service where institutions, as well as retail investors, can have priority access to all our research. We also have a wide distribution of our research reports across some of the top global financial platforms. Apart from equity research and credit research, we also provide advisory services with respect to mergers & acquisitions (M&A), private equity/ venture capital fundraising, valuation reports, and investment management services for corporates.
Baptista Research is owned and managed by Ishan Majumdar, an ex-Venture Capitalist/ Investment Banker, a Chartered Accountant, and a Masters’ degree holder in Management from HEC Paris. Ishan has nearly a decade of experience in Mergers and Acquisitions, Leveraged Buyouts (LBOs), Venture Capital Investing, Corporate Strategy, and Valuation in front-office roles at the likes of BNP Paribas CIB, Credit Agricole CIB, Groupe Danone, and TIW Private Equity. He has worked on and closed multiple acquisition deals, leveraged buyouts, and start-up investment transactions.

Equity Bottom-Up

<ul><li>Gilead Sciences Inc. showcased a solid performance for the second quarter of 2024, marked by robust commercial execution and growth across key therapeutic areas such as HIV, liver diseases, and oncology.</li><li>Notably, Biktarvy, an HIV treatment, observed an 8% year-over-year growth, while Trodelvy in oncology saw a 23% increase, and cell therapy revenues increased by 11%.</li><li>Additionally, the company reported disciplined management of operating expenses which significantly contributed to bottom-line growth.</li></ul>

Gilead Sciences Inc. showcased a solid performance for the second quarter of 2024, marked by robust commercial execution and growth across key therapeutic areas such as HIV, liver diseases, and oncology.Notably, Biktarvy, an HIV treatment, observed an 8% year-over-year growth, while Trodelvy in oncology saw a 23% increase, and cell therapy revenues increased by 11%.Additionally, the company reported disciplined management of operating expenses which significantly contributed to bottom-line growth.

Gilead Sciences: Innovations in Oncology & Cellular Therapy Along With Anti-Viral Focus! - Major Drivers

<ul><li>Gilead Sciences Inc. reported a solid first quarter of 2024.</li><li>Total product sales, exclusive of Veklury, rose 6% year-over-year to $6.1 billion.</li><li>Growth was driven primarily by demand across its HIV, oncology, and liver disease verticals.</li></ul>

Gilead Sciences Inc. reported a solid first quarter of 2024.Total product sales, exclusive of Veklury, rose 6% year-over-year to $6.1 billion.Growth was driven primarily by demand across its HIV, oncology, and liver disease verticals.

Gilead Sciences: Acquisition of CymaBay Therapeutics Enhancing Liver Disease Portfolio & 6 Major Drivers

<ul><li>Gilead Sciences exhibited a sturdy performance in 2023, driven by a 7% growth in product sales, excluding revenue from Veklury.</li><li>Significant sales growth was witnessed in HIV and oncology, with HIV sales growing by about $1 billion and oncology sales growing 37%, largely offsetting the decline in Veklury revenue.</li><li>The robust growth in product sales paves the way for Gilead's outlook for 2024 and its commitment to addressing high-demand clinical portfolios.</li></ul>

Gilead Sciences exhibited a sturdy performance in 2023, driven by a 7% growth in product sales, excluding revenue from Veklury.Significant sales growth was witnessed in HIV and oncology, with HIV sales growing by about $1 billion and oncology sales growing 37%, largely offsetting the decline in Veklury revenue.The robust growth in product sales paves the way for Gilead's outlook for 2024 and its commitment to addressing high-demand clinical portfolios.

Gilead Sciences: A Tale Of Continued Growth in Oncology and HIV Sectors! - Major Drivers

<ul><li>Gilead Sciences, Inc. delivered an all-around beat in the previous quarter, showcasing a 5% increase in the base business compared to the same period in 2022.</li><li>Biktarvy achieved a remarkable 12% growth from the corresponding quarter in 2022.</li><li>The increasing adoption of Trodelvy, a TROP-2-directed ADC, and cutting-edge cell therapies further fueled this upward trajectory.</li></ul>

Gilead Sciences, Inc. delivered an all-around beat in the previous quarter, showcasing a 5% increase in the base business compared to the same period in 2022.Biktarvy achieved a remarkable 12% growth from the corresponding quarter in 2022.The increasing adoption of Trodelvy, a TROP-2-directed ADC, and cutting-edge cell therapies further fueled this upward trajectory.

Gilead Sciences Inc.: 3 Major Drivers That Can Propel This Pharma Giant Forward! - Financial Forecasts

Research from Water Tower Research, Water Tower Research

Water Tower Research

Research from Water Tower Research

Water Tower Research is a leading equity research firm that provides research on micro, small and mid cap companies.

Water Tower Research was founded by Wall Street veterans after witnessing a fundamental shift in the investment research industry with the result being a declining knowledge base among investors, a lack of awareness and a shrinking pool of fundamental research being conducted on companies across the small-cap and micro-cap spectrum. The same issues are now increasingly occurring in the mid-cap space. This sea change within the investment community is impacting not only the companies themselves but also current shareholders and potential investors. With significantly less active sell-side sponsorship by Wall Street, a substantial information gap has developed between companies and various constituents in the financial community. The net result is fewer channels for insight and information to flow between companies and investors.

Equity Research Firm

Thematic (Sector/Industry)

<ul><li>We review last week’s biopharma news for meaningful clinical data, regulatory updates, research innovation, and M&amp;A.</li><li>Last week, LBPH was acquired, providing a boost to comps PRAX, MRNS, JAZZ, and DRUG.</li><li>Biopharma M&amp;A may start seeing an uptick after a slow summer.</li></ul>

We review last week’s biopharma news for meaningful clinical data, regulatory updates, research innovation, and M&amp;A.Last week, LBPH was acquired, providing a boost to comps PRAX, MRNS, JAZZ, and DRUG.Biopharma M&amp;A may start seeing an uptick after a slow summer.

Biopharma Week in Review - October 21, 2024

United States

Gilead Sciences, Inc. is a research-based biopharmaceutical company that discovers, develops, and commercializes therapeutics to advance the care of patients suffering from life-threatening diseases.  The Company's primary areas of focus include HIV/AIDS, liver disease and serious cardiovascular and respiratory conditions.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Gilead Sciences (GILD US)

Gilead Sciences: Innovations in Oncology & Cellular Therapy Along With Anti-Viral Focus! - Major Drivers

Gilead Sciences Inc. showcased a solid performance for the second quarter of 2024, marked by robust commercial execution and growth across key...

Baptista Research

Gilead Sciences: Acquisition of CymaBay Therapeutics Enhancing Liver Disease Portfolio & 6 Major Drivers

Gilead Sciences Inc. reported a solid first quarter of 2024. Total product sales, exclusive of Veklury, rose 6% year-over-year to $6.1...

Baptista Research

Gilead Sciences: A Tale Of Continued Growth in Oncology and HIV Sectors! - Major Drivers

Gilead Sciences exhibited a sturdy performance in 2023, driven by a 7% growth in product sales, excluding revenue from Veklury. Significant sales...

Baptista Research

Gilead Sciences Inc.: 3 Major Drivers That Can Propel This Pharma Giant Forward! - Financial Forecasts

Gilead Sciences, Inc. delivered an all-around beat in the previous quarter, showcasing a 5% increase in the base business compared to the same...

Baptista Research

Biopharma Week in Review - October 21, 2024

Last week, LBPH was acquired, providing a boost to comps PRAX, MRNS, JAZZ, and DRUG. Biopharma M&A may start seeing an uptick after a slow summer.

Water Tower Research

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)